Anti-human CCR1 monoclonal antibody
US11912775B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jul 18, 2018 |
| Grant date | Feb 27, 2024 |
| Priority date | — |
| Expiry date | Jul 18, 2038 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/70596
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
A monoclonal antibody is provided which binds to a human CC chemokine receptor 1 (CCR1) and inhibits activation of the human CCR1, or an antibody fragment thereof. The monoclonal antibody binds to an extracellular region of a human CCR1 and inhibits activation of the human CCR1 by a human CC chemokine ligand 15 (CCL15). An antibody fragment thereof, a hybridoma producing the antibody, a nucleic acid having a nucleotide sequence encoding the antibody or the antibody fragment, a transformant cell containing a vector containing the nucleic acid, a method for producing the antibody or the antibody fragment using the hybridoma or the transformant cell; a therapeutic agent and a diagnostic agent containing the antibody or the antibody fragment, and a method for treating and diagnosing a CCR1-related disease using the antibody or the antibody fragment are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.